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Abstract 
Background:  To compare hydroxyurea plus iron 
chelation therapy with iron chelation therapy alone 
in controlling iron overload in children with beta 
thalassaemia major.   
Methods:  In this comparative study  forty 
thalassaemia  major, cases undergoing routine blood 
transfusion, were observed in iron chelation plus 
hydroxyurea group (n=20) and iron chelation therapy 
alone (n=20).  The study outcome was measured in 
terms of impact of continuous blood transfusions on 
the size of liver ,spleen and Serum. Ferritin levels 
when compared among those given iron chelation 
therapy with hydroxyurea and those given iron 
chelation alone.    
Results: Mean age of patients was comparable 
among the two groups. Overall, males were slightly 
greater in proportion than females (52.5% versus 
47.5%). The mean liver size, spleen size and ferritin 
levels were significantly low in hydroxyurea group 
compared to no hydroxyurea group (p-value, <0.001).  
Conclusion: Hydroxyurea plus iron chelation 
therapy is better than iron chelation therapy alone in 
controlling iron overload in terms of enlargement of 
liver, and also limiting iron stores. 
Keywords: Beta thalassaemia, Transfusion 
dependent , Iron chelation, Hydroxyurea 
 
Introduction 
Beta thalassaemia is a prevalent genetic disorder and 
commonly presents in paediatric age group.1 The 
routine symptoms of beta thalassaemia is inability to 
synthesize haemoglobin due to failure in 
haematopoietic process. The incidence of the disease 
varies from 3-100/100000 population. Some estimates 
suggest that more than 25000 people with beta 
thalassaemia are living in Iran.2 Every year more than 
60000 babies are born with thalassaemia major 
worldwide and more than 80 million cases have 
positive thalassaemia carrier state.3  Beta 
thalassaemiais  is specified by chronic and severe 
haemolytic anaemia manifestation, lack of proper 
growth, enlargement of the spleen, and liver,iron 
overload and bone deformities, with especially visible 
changes in facial bones.4  
Treatment for β-thalassemia involves regular blood 
transfusion and disposal of excess iron from the body, 
especially liver. Though survival of patients has 
improved many folds, regular transfusion has many 
medical risks which may have role in depletion of 
quality of life.5 The consequences of liver and spleen 
enlargement vary, the improper blood production and 
containment results in weakness of bones, muscles and 
body systems. This anaemic condition puts a patient 
on the risk of cardiac decompensation, renal or hepatic 
failure. Excess iron is extremely toxic to all cells of the 
body and can cause serious and irreversible organic 
damage, such as cirrhosis, diabetes, heart disease, and 
hypogonadism. Fibrosis of the liver correlates directly 
with the age, number of units transfused, and the liver 
iron concentration. 6 
The amount of fetal hemoglobin  in red cell plays a 
major role in determining the severity of thalassemia. 
The increase in gamma globin chain synthesis 
decreases the alpha chain imbalance and improves the 
anemia. Multiple drugs have been studied to increase 
hemoglobin F. Histone deacetylase (HDAC) inhibitors 
such as butyrate and short-chain fatty acids revealed a 
modest response . 5-azacytidine initially shows 
favourable results , but was abandoned because of 
toxicity. Erythropoietin has increased fetal hemoglobin 
and total hemoglobin, particularly in patients with 
relatively low levels of erythropoietin. However, the 
long-term benefit is unknown, and the risk of marrow 
expansion is a cause for concern. The most successful 
fetal hemoglobin agent to date is oral 
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hydroxyurea. Hydroxyurea is a cytotoxic drug that is 
short-acting and relatively easy to monitor. It is FDA-
approved for the treatment of severe sickle cell 
disease.  It is less effective and predictable in 
thalassemia and more likely to be beneficial in 
thalassemia intermedia  cases and with those with 
xmn plymorphisim . 7 
 
Patients and Methods 
This comparative study   was conducted in the Bone 
Marrow Transplant Unit at the Children Hospital, 
PIMS, Islamabad.  Patients were divided into two 
groups on the basis of iron chelation therapy with 
hydroxyurea (n=20) or without hydroxyurea (n=20). In 
the interventional arm patients were given 
hydroxyurea along with iron chelation therapy after 
blood transfusion whereas in the control arm iron 
chelation therapy alone was given after blood 
transfusion,the cannula was saved and used for the iv 
chelation for the next 7 day with the dose of 50mg/kg 
iv desferal which was switched to oral deferrasirox 
40mg/kg for next 03 weeks. Hydroxyurea was 
continued with the dose of 20mg/kg daily without any 
gap. Patients of paediatric age (up to 12 years) were 
enrolled. For maintenance of quality and continuity of 
data, all the study process was conducted by the 
researcher herself. The study outcome was measured 
in terms of impact of continuous blood transfusions on 
the size of liver ,spleen and Serum Ferritin levels when 
compared among those given iron chelation therapy 
with hydroxyurea and those given iron chelation 
alone.  Data was entered and analyzed in SPSS version 
16.0. The quantitative variables like age and liver and 
spleen size were measured as mean and standard 
deviation whereas the categorical variables like gender 
was measured as frequency and percentages. The 
mean liver size was compared between the two groups 
using student’s t-test using a significance level of 0.05 
as cutoff.   
Results 
 The mean age of patients was equal in the two groups, 
4.22 ± 0.59 years in hydroxyurea group compared to 
4.32 ± 0.59 years in no hydroxyurea group (Table 1).  
There were 9 (45.0%) females in hydroxyurea group 
compared to 11 (55.0%) males. However, in no 
hydroxyurea group both males 10 (50.0%) and females 
10 (50.0%) were equally distributed. The mean size of 
spleen (cm) and liver (cm) ,serum ferritin levels 
(ng/ml) was found equal among the two study groups 
at baseline. The size of liver got significantly decreased 
after combination of hydroxyurea intervention (4.64 ± 
0.49 cm to 2.38 ± 0.25 cm). It was also found 
significantly different post intervention among 
hydroxyurea and no hydroxyurea groups (p-value, 
<0.001). Similarly, the size of spleen was also found 
significantly reduced after intervention (3.45 ± 0.31 cm 
to 1.91 ± 0.17 cm) .The mean size of spleen after 
intervention was found significantly decreased in 
hydroxyurea group compared to no hydroxyurea 
group (1.91 ± 0.17 vs 2.94 ± 0.27, p-value, <0.001).  
 
Table 1: Age of patients in the two study groups 
 Hydroxyurea 
(n=20) 
No Hydroxyurea 
(n=20) 
p-value 
Age categories (years) 
    3-3.99 7 (35.0%) 8 (40.0%)  
0.80    4.0-4.99 10 (50.0%) 8 (40.0%) 
   5.0 or above 3 (15.0%) 4 (20.0%) 
 Mean ± SD 4.22 ± 0.59 4.32 ± 0.59 0.61 
 
Table 2: Comparison of outcomes between the 
two study groups 
 Hydroxyurea 
(n=20) 
No 
Hydroxyurea 
(n=20) 
p-value 
Baseline liver size (cm) 
    Mean ± SD 4.64 ± 0.49 4.80± 0.46 0.31 
 Post intervention 
liver size (cm) 
  
    Mean ± SD 2.38 ± 0.25 3.87 ± 0.45 < 0.001 
Baseline spleen size (cm) 
    Mean ± SD 3.45 ± 0.31 3.55 ± 0.29 0.32 
 Post intervention 
spleen size (cm) 
  
    Mean ± SD 1.91 ± 0.17 2.94 ± 0.27  < 0.001 
Baseline ferritin level (ng/ml) 
    Mean ± SD 5560.0 ± 368.1 5495.4± 507.7  0.11 
Post intervention 
ferritin level (ng/ml) 
  
    Mean ± SD 3202.5 ± 225.8 4158.4± 507.7  <0.001 
 
 
Figure  1: Post intervention comparison of liver size among 
two groups 
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Figure  2: Post intervention comparison of spleen size 
among two study groups  
 
The baseline ferritin level was found to be comparable 
among the two groups, however, post intervention the 
mean ferritin was 3202.5 ± 225.8 ng/ml in iron 
chelation plus hydroxyurea group compared to 4158.4 
± 507.7 ng/ml in no hydroxyurea group. This 
difference was found significant between the two 
groups (p-value, <0.001). (Table 2) and (Figure  1& 2) 
 
Discussion 
In the present study a significant decrease in the liver 
and spleen size was witnessed in beta thalassaemia 
patients given hydroxyurea with iron chelation 
therapy compared to those given iron chelation alone. 
The role of hydroxyurea in depletion of ferritin level 
has been witnessed by some investigators in the region 
before as well.8-11 A study in India witnessed this trend 
as well as a study by Alibouyeh M et al from Iran 
reported that hydroxyurea significantly decreased 
ferritin levels in cases where an overload was present 
before intervention.8,9 
Hydroxyurea is a DNA antimetabolite increases stress 
erythropoises by increasing fetal heamoglobin (HbF). 
Achieving a gap of few days in transfusion every 
month brings marked annual reduction of  transfusion 
and consequently infused iron through blood is also 
cut down. Resulting achievement of less infused 
ironand consequently control on hepatospleenomegaly 
is a major step towards better management of 
thalasemia. 10,11 
Iron over load has critical manifestations for liver, 
spleen, heart as these patients can easily develop 
fibrosis or later on cirrhosis, hepatic 
failure,hypersplenism,cardiac  decompensation, 
endocrine complication. Thus, controlling iron 
overload promises a better organ functioning and 
maintainenceof iron level in the body.11,12 
Though, hyper-transfusion has resulted in better life 
expectancy of thalassaemic patients. However, iron 
overload is an unavoidable complication suffered by 
thalassaemia major patients as a consequence of 
continuous blood transfusions. Some investigators call 
it a “second disease” during treatment of first.12 
It has been concluded by many that liver cirrhosis 
hypersplenism,cardiac decompensation  and 
endocrine complication are all co-related to increased 
serum ferritin levels in the body.13 Over the recent 
decades, the management of thalassaemia major is 
improved dramatically to that extent that patients’ life 
expectancy has much increased.14 
These outcomes result from safer blood transfusions, 
the availability of three iron chelators, new imaging 
techniques that allow specific organ assessment of the 
degree of iron overload.15 There is, therefore, a need 
for quantitative, non-invasive methods for measuring 
body iron that are safer, accurate and easily available. 
The overload status of iron can be assessed by 
different techniques i.e. laboratory investigations. 
Serum ferritin measurement gives one quantitative 
finding whereas ultrasound of liver can tell only  the 
alteration in the normal shape and size of 
liver.16Although New technique T2* MR imaging gives 
more reliable concentration of liver and cardiac iron 
but  because of non availability of these methods  in 
our hospital we only relied only on  serum Ferritin, 
non invasive test done from single focal laboratory. 
The liver,spleen and other body organs are the major 
site of iron overload, containing 70% or more of body 
iron content. Liver iron correlates closely with total 
body iron in transfusional iron overload and total 
body iron.17 
Beta thalassaemia is a lifelong haemopoeteic disorder, 
the study on these cases has many advantages for the 
patients and community. Iron overload is a serious 
side effect of transfusions in these patients and 
assessment of the intervention of hydroxyurea was an 
additional benefits for these cases and their families. 
Since every patient is not lucky enough to find 100%  
HLA matched donor. If a child is deprived of matched 
related donor  even then he should be in optimum 
health for comfortable life. For bone marrow 
transplant iron reduction and downstaging (reduction 
in size of liver and spleen) is a pre requisite. 
Fortunately no complications related to chelation or 
hydroxyurea therapy was seen. The current study 
findings clearly differentiate the effects of 
hydroxyurea on the size of liver and spleen and serum 
 ferritin levels , however, it is mandated that large 
scale randomized trials must be conducted to validate 
the results of the current study at national and 
international level. 
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Conclusion 
A combination of hydroxyurea and iron chelation 
therapy is better than iron chelation therapy alone in 
controlling enlargement of spleen , and also limiting 
iron stores within adequate range. 
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